Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic.
Louise RathWei Zhen YehAngie RoldanRobb WesselinghMichael ZhongTracie TanNabil SeeryFrancesca BridgeYiChao FoongOlga SkibinaCassie NesbittHelmut ButzkuevenMastura MonifAnneke van der WaltPublished in: BMJ neurology open (2024)
Tixagevimab/cilgavimab administration did not protect against subsequent COVID-19 in our cohort. Compliance with uptake was influenced by administration location.